

Diabetes Monitoring for People with Schizophrenia and Diabetes

CBH is committed to ensuring members receive quality care. This measure assesses adults 18 to 64 years of age with schizophrenia and diabetes, who had both an LDL-C test and HbA1c test during the measurement year. People with serious mental illness who are taking an antipsychotic medication and have diabetes should be monitored to prevent worsening of health conditions.

NCQA Reference: [ncqa.org/hedis/measures/diabetes-and-cardiovascular-disease-screening-and-monitoring-for-people-with-schizophrenia-or-bipolar-disorder/](https://www.ncqa.org/hedis/measures/diabetes-and-cardiovascular-disease-screening-and-monitoring-for-people-with-schizophrenia-or-bipolar-disorder/)

Best Practices

- ➔ Monitor members with diabetes and schizophrenia at least annually, particularly those who do not have regular contact with a primary care physician (PCP).
 - » LDL-C and HbA1c are indicated for monitoring.
 - » Inform members when labs are due and help members find a lab location close to their homes
- ➔ Monitoring for diabetes is indicated when:
 - » Medications are initiated, changed, or titrated;
 - » Three to four months after medication is initiated; and
 - » Annually thereafter.
- ➔ Discuss results with members and refer to PCP as appropriate.
- ➔ Collaborate with case management and PCPs on member care strategies. Ensure the results are communicated in a timely fashion to other healthcare providers involved in the care of the member.
- ➔ Perform other recommended monitoring, such as: blood pressure, weight, regularly updated medical history, and medical lists.

Schizophrenia Diagnoses Associated With This Measure

- ➔ [F20.0] Paranoid Schizophrenia
- ➔ [F20.1] Disorganized Schizophrenia
- ➔ [F20.2] Catatonic Schizophrenia
- ➔ [F20.3] Undifferentiated Schizophrenia
- ➔ [F20.5] Residual Schizophrenia
- ➔ [F20.81] Schizophreniform Disorder
- ➔ [F20.89] Other Schizophrenia
- ➔ [F20.9] Schizophrenia, Unspecified
- ➔ [F25.0] Schizoaffective Disorder, Bipolar Type
- ➔ [F25.1] Schizoaffective Disorder, Depressive Type
- ➔ [F25.8] Other Schizoaffective Disorders
- ➔ [F25.9] Schizoaffective Disorder, Unspecified

Lab Screenings Associated With This Measure

HbA1c Test

CPT: 83036, 83037

LDL-C Test

CPT: 80061, 83700, 83701, 83704, 83721

Diabetes Monitoring for People with Schizophrenia and Diabetes

Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes Screening for Metabolic Syndrome Components

<i>Parameter</i>	<i>Suggested Frequency</i>
Personal and Family History (Obesity, Diabetes, Dyslipidemia, Hypertension, Coronary Heart Disease)	Annually
Height, Weight, BMI	Every 4 weeks for the first 12 weeks, then every 3 months
Waist Circumference	Annually
Blood Pressure, Pulse, Fasting Blood Glucose, Lipid Profile	12 weeks, then annually

Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Diabetes Care. 2004;27(2):596-601. doi.org/10.2337/diacare.27.2.596

Resources

NCQA: Comprehensive Diabetes Care (CDC)
[ncqa.org/hedis/measures/comprehensive-diabetes-care/](https://www.ncqa.org/hedis/measures/comprehensive-diabetes-care/)

NCQA Letter: NCQA Supports Medicaid Behavioral Measure Reporting
[ncqa.org/comment-letter/ncqa-supports-medicaid-behavioral-measure-reporting/](https://www.ncqa.org/comment-letter/ncqa-supports-medicaid-behavioral-measure-reporting/)

Centers for Medicare & Medicaid Services Measures Inventory Tool
[cmit.cms.gov/cmit/](https://www.cms.gov/cmit/)

Centers for Disease Control and Prevention: All About Your A1C
[cdc.gov/diabetes/managing/managing-blood-sugar/a1c.html](https://www.cdc.gov/diabetes/managing/managing-blood-sugar/a1c.html)

Lab Coverage Information

<i>Health Plan</i>	<i>Laboratory Provider</i>
Community Behavioral Health	Atlantic Diagnostics and Parkway Clinical Laboratories
Aetna Better Health	Quest Diagnostics
Health Partners Plans	Quest Diagnostics
Keystone First	LabCorp
United Healthcare	LabCorp and Quest Diagnostics

Disclaimer: The information contained in this tip sheet is for educational and informational purposes only. The clinical services described in this tip sheet may not be covered for all CBH enrollees. To find out about what services are available to you under the CBH benefit package, please contact CBH Provider Operations at 215-413-3100.

This document was developed in partnership with collaborating providers and the Southeastern Pennsylvania Medicaid MCOs that participate in the HealthChoices and Community HealthChoices programs.